BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

In the Claims

Please add the following new claims:

23. A method for treating disease, organ disease, damage, and/or failure, organ system disease, damage, and/or failure, incipient organ disease, damage, and/or failure, or tissue disease, damage, and/or failure comprising the administration of a therapeutically effective amount of a composition comprising a combination of cellular, cell membrane, and extracellular matrix derived ingredients to a human.

24. The method according to claim 23, wherein said therapeutically effective amount of said composition reduces or eliminates signs or symptoms of disease, organ, organ system, incipient organ, tissue disease, damage, and/or failure or abnormal clinical findings associated therewith.

25. The method according to claim 23, wherein said composition is administered in an oral solid dosage form or a liquid.

26. The method according to claim 23, wherein said solid oral dosage form is a capsule, tablet, or a flavored powder.

27. The method according to claim 23, wherein said composition is administered topically to a dermatologic, ophthalmic, or gastrointestinal site.

28. The method according to claim 26, wherein said solid dosage form comprises cellular components of about 250 mg to about 500 mg; cell membrane components of about 250 mg to about 500 mg; and extracellular matrix components of about 250 mg to about 500 mg.

29. The method according to claim 28, wherein said solid dosage form comprises cellular components of about 250 mg; cell membrane components of about 250 mg; and extracellular matrix components of about 250 mg.

30. The method according to claim 27, wherein about three to four capsules are administered to said human about three to six times daily.

31. The method according to claim 30, wherein said capsules are not re-administered to said human more frequently than about every four to six hours.

32. A method for treating, aborting, or averting organ disease, damage, and/or failure comprising the administration of a therapeutically effective amount of a composition comprising a combination of naturally-derived or synthetically produced cellular, cell membrane, and extracellular matrix derived ingredients to a human.

33. A method for treating organ failure or the need for transplantation of an organ comprising the administration of a therapeutically effective amount of a composition comprising a combination of naturally-derived or synthetically produced cellular, cell membrane, and extracellular matrix derived ingredients to a human.

34. A method for stimulating cell growth comprising the administration of a composition comprising a combination of cellular, cell membrane, and extracellular matrix derived ingredients in an amount effective to stimulate cell growth.

35. The method according to claim 34, wherein said method stimulates the growth of stem cells.

36. A method of treating a condition or disorder associated with diseased tissue, damaged tissue, damaged organ(s), failed organ(s) or a failed organ system comprising the administration of a therapeutically effective amount of a composition comprising a combination of cellular, cell membrane, and extracellular matrix derived ingredients to a mammal.

37. The method according to claim 36, wherein said condition or disorder is congenital biliary atresia.

38. The method according to claim 36, wherein said condition or disorder is Crohn's disease.

39. The method according to claim 36, wherein said mammal is a human.

40. The method according to claim 37, wherein said mammal is a human.

41. The method according to claim 38, wherein said mammal is a human.

42. The method according to claim 23, wherein said composition is administered during the prodromal phase of organ failure or the prodromal phase of incipient organ failure.

43. The method according to claim 36, wherein said damaged tissue has been damaged by a burn.

44. The method according to claim 36, wherein said damaged organ(s)/tissue(s), failed organ(s)/tissue(s) or a failed organ/tissue system is(are) ophthalmic, dermatological, respiratory tract, gastrointestinal, hepatic, the immunological system, neurologic, cardiovascular, musculoskeletal joint, endocrine, exocrine, hematologic, or renal.

45. A therapeutic composition or anti-inflammatory medicament comprising:

a) at least one extracellular matrix compound;

b) at least one polar surface active lipid; and

c) at least one optically pure essential L-amino acid.

46. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said extracellular matrix compound is synthetically produced.

Sub F2

47. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said extracellular matrix compound is derived from cellular or tissue sources.

48. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said polar surface active lipid is derived from cellular or tissue sources.

49. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said polar surface active lipid is synthetically produced.

C6

50. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said optically pure essential L-amino acid is synthetically produced.

Sub F3

51. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said optically pure essential L-amino acid is derived from cellular or tissue sources.

52. The therapeutic composition or anti-inflammatory medicament according to claim 47, wherein said cellular or tissue sources are cell membranes, tissues, or organs.

53. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said extracellular matrix compound is selected from the group consisting of glycosaminoglycans, collagens, cartilage, chrondroitin sulfate, glycoproteins, and proteoglycans.

54. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said polar surface active lipids are selected from the group consisting of phospholipids, glycolipids, and lipoproteins.

55. The therapeutic composition or anti-inflammatory medicament according to claim 45, wherein said amino acids are aliphatic amino acids.

56. The therapeutic composition or anti-inflammatory medicament according to claim 55, wherein said aliphatic amino acids contain short chain fatty acids.

57. The therapeutic composition or anti-inflammatory medicament according to claim 56, wherein said amino acids contain ammoniated short chain fatty acids at the alpha carbon position.

Sub F4

58. The therapeutic composition or anti-inflammatory medicament according to claim 55, wherein said amino acids are L-glycine, L-alanine, L-leucine, L-isoleucine, L-threonine, L-cysteine, L-methionine, L-cystine, L-serine, and/or L-valine.

59. The therapeutic composition or anti-inflammatory medicament according to claim 58, wherein said therapeutic composition or anti-inflammatory medicament contains amino acids in molar ratios equivalent to the molar ratios of amino acids in cyclosporin.

Sub F5

60. The therapeutic composition or anti-inflammatory medicament according to claim 59, wherein said amino acids are L-glycine, L-alanine, L-leucine, and L-valine.

61. The therapeutic composition or anti-inflammatory medicament according to claim 57, wherein said amino acid contains butyric acid as the short chain fatty acid.

62. The therapeutic composition or anti-inflammatory medicament according to claim 61, wherein said amino acid is L-valine.

63. The therapeutic composition or anti-inflammatory medicament according to claim 61, wherein said amino acid is L-methionine.

64. The therapeutic composition or anti-inflammatory medicament according to claim 61, wherein said amino acid is gamma amino butyric acid.

65. The therapeutic composition or anti-inflammatory medicament according to claim 45, further comprising a sterile vehicle.

66. The therapeutic composition or anti-inflammatory medicament according to claim 48, wherein said cellular or tissue sources are cell membranes, tissues, or organs.

67. The therapeutic composition or anti-inflammatory medicament according to claim 51, wherein said cellular or tissue sources are cell membranes, tissues, or organs.

68. The therapeutic composition or anti-inflammatory medicament according to claim 49, wherein said polar surface active lipids are selected from the group consisting of phospholipids, glycolipids, and lipoproteins.

69. The therapeutic composition or anti-inflammatory medicament according to claim 48, wherein said polar surface active lipids are selected from the group consisting of phospholipids, glycolipids, and lipoproteins.

70. The therapeutic composition or anti-inflammatory medicament according to claim 48, wherein at least one extracellular matrix compound, at least one polar surface active lipid, and at least one optically pure essential L-amino acid associate through molecular bonding forces.

71. The therapeutic composition or anti-inflammatory medicament according to claim 70, wherein said molecular bonding forces are electron affinity, van der Waals forces, and/or zwitterionic.

72. The therapeutic composition or anti-inflammatory medicament according to claim 59, wherein components of said therapeutic composition or anti-inflammatory medicament associate through molecular bonding forces.

73. The therapeutic composition or anti-inflammatory medicament according to claim 72, wherein said molecular bonding forces are electron affinity, van der Waals forces, and/or zwitterionic.

74. The composition according to claim 45, further comprising: (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc; (f) zinc oxide; (g) Vitamin A; (h) chrondroitin sulfate; (i) cartilage; (j) collagen; or any combination of (a) through (j).

75. The therapeutic composition or anti-inflammatory medicament according to claim 59, further comprising: (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc; (f) zinc oxide; (g) Vitamin A; (h) chrondroitin sulfate; (i) cartilage; (j) collagen; or any combination of (a) through (j).

76. The therapeutic composition or anti-inflammatory medicament according to claim 48, further comprising: (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc; (f) zinc oxide; (g) Vitamin A; (h) chrondroitin sulfate; (i) cartilage; (j) collagen; or any combination of (a) through (j).

77. The therapeutic composition or anti-inflammatory medicament according to claim 73, further comprising: (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc; (f) zinc oxide; (g) Vitamin A; (h) chrondroitin sulfate; (i) cartilage; (j) collagen; or any combination of (a) through (j).

78. The therapeutic composition or anti-inflammatory medicament according to claim 71, wherein said composition provides biochemically key components that pharmacodynamically continue bonding effects in reorganization, regrowth, and regeneration of normal tissue or disease tissue.

79. The therapeutic composition or anti-inflammatory medicament according to claim 73, wherein said composition provides biochemically key components that pharmacodynamically continue bonding effects in reorganization, regrowth, and regeneration of normal tissue or disease tissue.

80. The therapeutic composition or anti-inflammatory medicament according to claim 71, wherein said molecular bonding forces are maximized in the internal milieu.

81. The therapeutic composition or anti-inflammatory medicament according to claim 73, wherein said molecular bonding forces are maximized in the internal milieu.

82. The therapeutic composition or anti-inflammatory medicament according to claim 59, wherein said milieu is mammalian.

83. The therapeutic composition or anti-inflammatory medicament according to claim 82, wherein said mammal is a human.

84. The method according to claim 32, wherein said composition is administered during the prodromal phase of organ failure or the prodromal phase of incipient organ failure.

85. The method according to claim 33, wherein said composition is administered during the prodromal phase of organ failure or the prodromal phase of incipient organ failure.

86. The method according to claim 23, wherein said organ disease, damage, and/or failure, organ system disease, damage, and/or failure, incipient organ disease, damage, and/or failure, or tissue disease, damage, and/or failure is associated with infection by human immunodeficiency virus.

87. The method according to claim 23, wherein said organ disease, damage, and/or failure, organ system disease, damage, and/or failure, incipient organ disease, damage, and/or

failure, or tissue disease, damage, and/or failure is associated with drug addiction or drug dependency.

C6

88. The method according to claim 23, wherein said disease is drug addiction or drug dependency.